Nanomedicines in Development
Arrogene is developing nanomedicine products for treatment of primary brain, lung, and triple negative breast cancer (AG101) and HER2-positive breast cancer and its metastasis (AG102).
In-vivo studies of AG101 demonstrated a 10-fold brain tumor reduction and significantly increased survival in animal models. These results show how AG101 works as ground-breaking anti-cancer nano medicine agent for blood-brain-barrier penetration, and suppression of untreatable brain and other cancers.
In pre-clinical animal trials, AG102 demonstrates a 50% higher tumor reduction than competing technologies in pre-clinical studies. Also, like AG101, AG102 overcomes drug resistance and systemic toxicity.